BMY

Business Context and Reporting Period

Company: Bristol-Myers Squibb Company
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2003
Context: The Company is a global pharmaceutical firm operating in Pharmaceuticals, Nutritionals, and Other Healthcare segments. The period is characterized by the continued workdown of U.S. wholesaler inventories, the application of the consignment revenue model for certain transactions, and significant ongoing litigation regarding antitrust and product liability matters.

Key Financial Metrics

Note: Debt figures calculated as Short-term borrowings ($1,902M) + Long-term debt ($6,422M). Working Capital calculated as Current Assets ($10,659M) - Current Liabilities ($8,430M).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 22% in Q2 2003 and 11% for the six-month period compared to 2002. Growth was driven by a 17% volume increase, favorable foreign exchange (4%), and price increases (1%).
• Profitability Surge: Net earnings from continuing operations increased 83% in Q2 and 24% for the six months. This was significantly aided by the absence of a $160 million in-process research and development charge recorded in Q1 2002 related to the ImClone transaction.
• Tax Rate Reduction: The effective income tax rate decreased to 21.3% in Q2 2003 (from 28.9% in 2002) and 24.2% for the six months (from 27.8% in 2002), primarily due to revised estimates on foreign tax credits following the reorganization of non-U.S. subsidiaries.
• Wholesaler Inventory Workdown: The Company continued to work down excess wholesaler inventory. $32 million of deferred revenue was recognized in Q2, and $287 million for the six months. Deferred revenue related to consignment inventory dropped to $110 million from $470 million at year-end 2002.
• Segment Performance:
  • Pharmaceuticals: Sales up 28% (Q2) and 14% (6 months). Strong growth in Pravachol, Plavix, and Sustiva offset by generic competition for Taxol in the U.S.
  • Nutritionals: Sales down 7% (Q2) and 6% (6 months), impacted by a $60 million charge related to WIC program rebates and declining U.S. infant formula sales.
  • Other Healthcare: Sales up 11% (Q2) and 7% (6 months), driven by ConvaTec and Medical Imaging.

Guidance, Outlook, Risks, and Unusual Items

Outlook and Guidance

• Exclusivity Losses: Management expects exclusivity losses to amount to approximately $1 billion in net sales annually over the next several years, largely due to the loss of exclusivity for Pravachol in the U.S.
• Offsetting Growth: These losses are expected to be offset by growth in in-line products (Plavix, Avapro, Sustiva), recently launched products (Abilify, Reyataz), and late-stage pipeline products (Erbitux, CTLA4-Ig, Entecavir).
• Cost Management: The Company expects to continue reviewing its cost base, which may result in future restructuring charges, though no specific amounts were estimated.

Unusual Items and Contingencies

• ImClone Investment: The Company recorded a $3 million net loss in Q2 and $26 million for the six months related to its share of ImClone's losses. The carrying value of the investment was $77 million, while the market value was approximately $460 million as of June 30, 2003.
• Restructuring: Charges of $25 million were recorded in Q2 2003 for manufacturing rationalization and workforce reductions (approx. 430 employees), partially offset by adjustments to prior reserves.
• Litigation Settlements: The Company recognized $41 million of litigation settlement income in Q2 2003. Significant settlements regarding Taxol ($135M) and Buspar ($535M) were announced in January 2003, with final court approvals pending in late 2003.

Material Risks

• Legal Proceedings: The Company faces significant pending litigation including antitrust suits (Taxol, Buspar), securities class actions (Vanlev, ImClone, wholesaler inventory issues), and product liability suits (PPA, Serzone, Stadol NS). Management believes the aggregate impact could be material to results of operations and cash flow.
• Government Investigations: The SEC and U.S. Attorney's Office are investigating wholesaler inventory issues and accounting practices. The Company is also under investigation regarding pricing and marketing practices for Medicare/Medicaid drugs.
• Internal Controls: The Company acknowledged two "material weaknesses" in internal controls identified by auditors in 2002 regarding accounting and financial reporting. Management concluded that disclosure controls were reasonably designed as of the evaluation date, but noted the ongoing nature of remediation.

Investor Verification Checklist

• Wholesaler Inventory Levels: Verify the status of the "orderly workdown" of U.S. wholesaler inventories and the impact of the consignment revenue model on future quarterly sales recognition.
• Litigation Finalization: Monitor the final court approval hearings for the Taxol and Buspar antitrust settlements scheduled for the second and fourth quarters of 2003, respectively.
• Government Investigations: Track the outcomes of the SEC and U.S. Attorney's Office investigations into wholesaler inventory incentives and accounting practices, as well as the internal review of anti-kickback compliance.
• Product Exclusivity: Assess the actual sales impact of the loss of exclusivity for Pravachol in the U.S. against the projected growth of new products like Abilify and Reyataz.
• ImClone Relationship: Monitor the financial performance of ImClone and the status of the Erbitux commercialization agreement, given the significant market value discrepancy between the investment's carrying value and market price.